Clinical Commissioning Policy: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation (all ages)

NHS England Reference: 170080P
Clinical Commissioning Policy: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation (all ages)

First published: November 2018

Prepared by NHS England Specialised Services Clinical Reference Group for Chemotherapy

Published by NHS England, in electronic format only.

Gateway reference: 07603
Contents

Policy statement ........................................................................................................... 4
Equality statement ......................................................................................................... 4
Plain language summary ............................................................................................... 4
1 Introduction .................................................................................................................. 6
2 Definitions ..................................................................................................................... 6
3 Aims and objectives ..................................................................................................... 7
4 Epidemiology and needs assessment .......................................................................... 7
5 Evidence base ............................................................................................................... 8
6 Documents which have informed this policy ............................................................. 9
7 Date of review .............................................................................................................. 9
References ...................................................................................................................... 10
Policy statement

NHS England will not routinely commission clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation in accordance with the criteria outlined in this document.

In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources.

This policy document outlines the arrangements for funding of this treatment for the population in England.

Equality statement

Promoting equality and addressing health inequalities are at the heart of NHS England’s values. Throughout the development of the policies and processes cited in this document, we have:

- given due regard to the need to eliminate discrimination, harassment and victimisation, to advance equality of opportunity, and to foster good relations between people who share a relevant protected characteristic (as cited under the Equality Act 2010) and those who do not share it; and

- given regard to the need to reduce inequalities between patients in access to, and outcomes from healthcare services and to ensure services are provided in an integrated way where this might reduce health inequalities.

Plain language summary

About acute myeloid leukaemia

Acute myeloid leukaemia (AML) is a type of blood cancer that affects the white blood cells, specifically myeloid cells. The disease is relatively rare and is often diagnosed in people above 65 years of age. It is considered to be an aggressive and rapidly progressing cancer that almost always requires immediate treatment.

AML causes white blood cells to be produced more quickly than normal and as a result the cells become abnormal because they grow and divide too fast. The abnormal myeloid cells build-up in the blood and bone marrow and eventually can spread to other parts of the body. People with AML will usually experience more infections, tiredness, high temperature, breathlessness and they may bruise or bleed more easily.
About current treatments

Treatment for AML is usually divided into two phases - induction and consolidation. The aim of the induction phase is to destroy the cancer cells, this is called inducing a remission. Following the induction phase, more treatment is given to stop, or consolidate, the cancer from returning. In both phases, chemotherapy is the main treatment option, however, some patients may also have a stem cell transplant as part of consolidation treatment.

In some cases, AML can return, or relapse, following a period of remission after first treatment. Some patients are resistant to the chemotherapy medicines that are used; this is called refractory disease. This policy relates to relapsed and refractory disease; this means that each patient will have had at least one prior, or first line, treatment.

About the new treatment

Clofarabine is a chemotherapy medicine which belongs to a group of drugs known as anti-metabolites. These drugs interfere with the growth of cancer cells and cause them to die. Clofarabine is delivered intravenously (injected into the bloodstream) and can be used to treat AML when combined with another drug called cytarabine, which is usually used to treat AML alone. In both cases, the aim of treatment is usually to induce remission and enable a stem cell transplant.

What we have decided

NHS England has carefully reviewed the evidence to treat relapsed or refractory acute myeloid leukaemia with clofarabine. We have concluded that there is not enough evidence to make the treatment available at this time.
1 Introduction

Acute Myeloid Leukaemia is a type of cancer affecting the blood, characterised by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production or normal blood cells leading to anaemia, bleeding problems and serious infections.

Symptoms may be related to bone marrow failure (causing anaemia, neutropenia and thrombocytopenia) or organ infiltration (usually liver or spleen). Fever is a common presenting sign, and symptoms include fatigue, dizziness, shortness of breath on exertion, bleeding and bone pain. AML develops rapidly and is fatal if not treated.

The aim of treatment for AML is usually to achieve a remission of the disease through suppression of the patient’s own haemopoetic cells (in the bone marrow). Once disease remission is achieved, a haemopoetic stem cell transplant (HSCT) can be given, replacing the haemopoetic system, but without the abnormal white blood cell line. A number of chemotherapy medicines are currently available to treat AML and provide a bridge to HSCT; for patients with refractory or relapsed AML, European LeukemiaNet guidelines recommend cytarabine (if not used for first induction), with or without an anthracycline (Döhner et al, 2010). Mitoxantrone plus etoposide and cytarabine (MEC) is another option for relapsed disease.

Clofarabine is a purine nucleoside antimetabolite – a form of systemic chemotherapy, which can be used in combination with cytarabine (another systemic chemotherapeutic agent) for the treatment of refractory or relapsed AML. It is not included in European AML guidelines and is not licensed for this indication.

Where clofarabine is given to treat relapsed and refractory AML, it is administered intravenously at a dose of 40mg/m2 daily on days one to five of a twenty-one day cycle.

2 Definitions

**Acute Myeloid Leukaemia (AML):** A form of aggressive (acute) leukaemia which affects the myeloid cells and causes the build-up of abnormal white blood cells.

**Clofarabine:** An anti-metabolite drug treatment which aims to treat leukaemia through interfering with the growth of abnormal cancerous cells.

**Complete Remission (CR):** No detectable disease following a course of treatment.

**Consolidation:** The second phase of treatment for cancers such as AML, which takes place after remission has been induced. This part of treatment aims to prevent a relapse from occurring.

**Hematopoietic stem cell transplantation (HSCT):** This is a form of stem cell transplantation that is used to treat certain patients with a range of malignant and
non-malignant blood-related disorders. It involves the use of stem cells (from the patient or a donor).

**Induction:** The first phase of treatment for cancers such as AML, which aims to induce remission. This part of treatment aims to destroy as many leukaemia cells as possible.

**Overall Survival (OS):** The length of time from either diagnosis or start of treatment that the patient is still alive.

**Progression Free Survival (PFS):** The length of time from either diagnosis or start of treatment to disease progression or patient death from any cause.

**Relapsed disease:** Describes when a condition has recurred following response to previous treatment; this may occur at any time following completion of treatment.

**Refractory disease:** Means that there has been no response to the immediately preceding treatment, patients have either progressed during treatment or have stable disease whenever treatment has been stopped.

### 3 Aims and objectives

This policy considered clofarabine as a treatment for refractory or relapsed AML with intent to bridge to transplant.

The objectives were to establish, via an evidence review, the following:

Does clofarabine improve response rate in patients with refractory or relapsed AML allowing them to undergo stem cell transplantation and thereby prolong survival?

### 4 Epidemiology and needs assessment

The incidence of AML in Europe is 5-8 cases per 100,000 people. In 2013, there were 2,942 new cases of AML in the UK. Based on current population estimates, the number of new cases in England in a given year will amount to approximately 2,489 (Cancer Research UK).

Incidence increases with age and median age of onset is 67 years. Between 2011 and 2013, about 55% of cases were diagnosed in people aged 70 years and over. Complete remission is achieved in 60-80% of patients (Patient.info).

Patients who do not achieve complete remission, or who subsequently relapse, usually undergo further chemotherapy, still with a view to achieving remission. Relapse occurs in over 50% of patients at some point.

In 2017, 48 people received clorfarabine through the Cancer Drugs Fund.
5 Evidence base

NHS England has concluded that there is not sufficient evidence to support the routine commissioning of this treatment for the indication.

Evidence summary

There is one randomised, controlled clinical trial of clofarabine in patients with refractory or relapsed AML (Faderl et al 2012). The CLASSIC I trial randomised 326 adults with relapsed or refractory AML to clofarabine 40mg/m² or placebo daily for five days, given as an intravenous infusion over one hour, followed three hours later by a two-hour infusion of cytarabine 1g/m².

Evidence for efficacy of clofarabine

Significantly more patients receiving clofarabine plus cytarabine achieved complete remission compared to patients receiving cytarabine monotherapy (35.2% vs. 17.8%; p<0.01). However, similar numbers of patients in each group subsequently underwent HSCT (about 20%). There was no significant difference between groups in the primary outcome of median overall survival (6.6 months with clofarabine plus cytarabine vs. 6.3 months with placebo plus cytarabine). Median disease-free survival was also similar between groups (8.1 months vs. 7.0 months, respectively). No comparison of post-transplant outcomes was reported for patients who did vs. those who did not go onto receive HSCT. The study enrolled patients aged at least 55 years, who had received no more than two previous induction regimens. It involved few European patients so the results may not be generalisable to the UK. In addition, the CLASSIC I trial was not designed to assess whether use of clofarabine allows more patients to undergo HSCT.

The authors of one retrospective study (Roberts et al, 2015) noted that only ten of the 65 patients who received clofarabine and cytarabine in their study would have been eligible for CLASSIC I, mostly because of younger age. In CLASSIC I, there were slightly more patients in the clofarabine group than in the placebo group with unfavourable/other cytogenetics (49.4% vs. 38.6%, respectively) and worse performance status (ECOG 2, 16.0% vs. 11.4%, respectively), indicating they were possibly less likely to respond to or tolerate treatment, but otherwise baseline characteristics were similar between groups.

CLASSIC I did not report overall survival rates for the subgroup of patients who proceeded to HSCT; for all enrolled patients, overall survival at two years was estimated by other investigators to be about 10% (Middeke et al, 2016), a rate much lower than reported in uncontrolled studies. A retrospective study involving 59 patients showed that clofarabine was not associated with improved survival compared to two mitoxantrone-containing regimens (Loeffler et al, 2015).

Evidence for safety of clofarabine

There was a high mortality rate of 16% in the first 30 days after administration of clofarabine and cytarabine, compared with 5% in patients treated with cytarabine
alone (p<0.01). Deaths were mostly due to adverse events, and this might explain why an increase in complete remission rate did not translate into improved overall survival. Serious adverse events occurred in 60% of patients given clofarabine and cytarabine, and 49% given cytarabine alone. Serious infections occurred in 38% of patients given clofarabine and cytarabine compared with 22% of patients given cytarabine alone. Most common grade 3 to 4 adverse events in the clofarabine group were febrile neutropenia, hypokalaemia, thrombocytopenia, pneumonia, anaemia, neutropenia, and increased liver enzymes.

Uncontrolled studies using doses of clofarabine ranging from 15mg/m² to 40mg/m², alone or with cytarabine, show it can be used as a bridge for reducing leukaemic burden prior to HSCT in some patients. However, these findings are at high risk of bias and are limited by patient, disease and treatment heterogeneity.

Conclusion

There is only one randomised controlled trial of clofarabine in refractory or relapsed AML in older adults aged at least 55 years, and this showed that adding clofarabine 40mg/m² daily for five days to treatment with cytarabine does not allow more patients to undergo HSCT or improve overall survival. However, the study was not designed to assess whether use of clofarabine allows more patients to undergo HSCT. More patients achieved complete remission with clofarabine and cytarabine than with cytarabine alone, but this was offset by more deaths due to adverse events. No comparison of post-transplant outcomes was reported for patients who did vs. those who did not go onto to receive HSCT.

The optimal role for clofarabine is unclear, and there are still questions to be answered about the balance between efficacy and toxicity of clofarabine. Insufficient evidence is available to determine the most appropriate dose and which patient groups are most likely to tolerate clofarabine.

6 Documents which have informed this policy

NHS England. 2016. Evidence review: Clofarabine as a treatment for refractory or relapsed acute myeloid leukaemia with intent to bridge to stem cell transplantation.

7 Date of review

This document will be reviewed when information is received which indicates that the policy requires revision.
References


